Welcome to our dedicated page for iSpecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iSpecimen Inc. filings document material events, governance matters, capital-structure changes, and reporting status for the company’s Nasdaq-listed common stock. Recent 8-K disclosures cover the completed 1-for-40 reverse stock split, related certificate amendments, Regulation FD press-release exhibits, shareholder meeting adjournments, and board composition changes.
The company’s regulatory record also includes emerging growth company disclosures and a Rule 12b-25 notice tied to its annual report filing process. These filings provide formal records of iSpecimen’s public-company obligations alongside its biospecimen marketplace operations.
iSpecimen Inc. reported voting results from its October 30, 2025 special meeting. Stockholders approved multiple capital actions, including a reverse stock split in a range of 1:10 to 1:100, an increase in authorized capital stock from 250,000,000 to 1,000,000,000, and approvals under Nasdaq Listing Rule 5635(d) for potential private financings and an equity line of credit that could exceed 19.99% of outstanding shares and occur below the Minimum Price.
As of the July 25, 2025 record date, 3,979,517 common shares were outstanding and entitled to vote. A quorum was present with 1,437,502 shares represented, approximately 36% of those entitled to vote. Stockholders also approved amending certain outstanding convertible securities to raise the conversion price floor from 50% to 80% of the lowest volume-weighted average price during the measurement period, and authorized other business properly brought before the meeting.
iSpecimen Inc. filed a universal shelf registration on Form S-3 to register up to $100,000,000 of securities, including common stock, preferred stock, debt securities, warrants, rights, and units. These may be offered and sold from time to time after effectiveness, with specific terms to be set by prospectus supplements.
Its common stock trades on Nasdaq as “ISPC.” The last reported sale price was $0.817 on October 20, 2025. The company cites an aggregate market value held by non‑affiliates of approximately $11,133,000, based on 9,771,028 shares and a $1.14 closing price on October 3, 2025. Under General Instruction I.B.6, primary offerings are limited to no more than one‑third of public float in any 12‑month period while the float remains below $75,000,000, and the company notes it has not sold securities under I.B.6 during the 12‑month period ending with this prospectus.
The prospectus also describes a planned corporate treasury program targeting up to $200,000,000 of Solana (SOL) acquisitions, with an initial financing targeted in Q4 2025, subject to market, regulatory, and corporate considerations, and details related risks, including volatility, regulatory uncertainty, custody/cybersecurity, liquidity for Locked SOL, and potential reputational impacts.
iSpecimen Inc. (ISPC) called a special shareholder meeting to approve several capital actions. The Board seeks authority to effect a reverse stock split at a ratio between 1-for-10 and 1-for-100, with the exact ratio set at the Board’s discretion, primarily to support compliance with Nasdaq’s $1.00 minimum bid price. The Board also asks to increase authorized capital from 250,000,000 to 1,000,000,000 shares.
The agenda includes two Nasdaq Listing Rule 5635(d) approvals: one for potential non‑public financings exceeding 19.99% of outstanding common stock or voting power (at a price that may be below the Minimum Price), and another to permit an equity line of credit with issuances that could also exceed 19.99%. Separately, the company seeks to amend certain outstanding convertibles to raise the conversion price floor from 50% to 80% of the lowest VWAP during the applicable period, which may reduce shares issuable upon conversion. An adjournment proposal is also included.
The Board recommends voting FOR all proposals. The meeting is virtual on October 30, 2025 at 10:00 a.m. ET for holders of record as of July 25, 2025.
iSpecimen, Inc. filed an amended S-1 registration that describes a transactional biospecimen marketplace with concentrated revenue, recent capital raises, material liabilities, and operational and legal risks. The company reports its common shares outstanding prior to and after the offering are based on 8,211,156 shares as of October 6, 2025, and discloses significant customer concentration (one customer accounted for approximately 29% of 2024 revenue). Revenue is transactional and non‑recurring, sourced when researchers place specimen orders. The filing discloses a $1.0M loan issued with an 18% interest rate, ongoing sales tax liabilities (hundreds of thousands of dollars), and litigation and platform‑service disputes that caused a temporary marketplace shutdown in early 2025.
The company received a Nasdaq deficiency notice for minimum stockholders’ equity requirements and has submitted a compliance plan. Capital raises in 2024 included an ATM program that generated gross proceeds of approximately $1.49M and a registered securities offering that generated aggregate gross proceeds near $4.999M. The filing emphasizes operational risks—supplier reliance, international expansion, regulatory compliance, and revenue variability—and discloses an accumulated deficit and limited cash resources, creating ongoing financing dependence.
iSpecimen, Inc. filed a preliminary revised proxy statement asking shareholders to approve a range of corporate actions at a Special Meeting. Key proposals include a reverse stock split selectable between 1-for-10 and 1-for-100, an increase in authorized shares, shareholder approval to permit issuances exceeding 19.99% under Nasdaq rules, amendments to a convertible floor, establishment of an equity line of credit (ELOC), and adjournment authority. The filing also discloses a planned corporate treasury program involving digital assets, retention of BlockArrow Capital as consultant, and an anticipated initial financing in Q4 2025 targeting at least $50 million and a longer-term objective of about $200 million over 12–24 months. The proxy explains voting mechanics, broker non-vote treatment, potential dilution, and risks tied to staking, locked Solana tokens, custodial and counterparty risks.
iSpecimen, Inc. (ISPC) amended its S-1 registration statement describing its business as a transactional biospecimen marketplace that sources remnant and research-use specimens from a global network of supply sites. The filing discloses specimen mix and supply-site counts (for example, ~44 clinical research centers, ~16 biorepositories, ~11 clinical lab sites, two blood donor centers and one cadaveric donation center as of December 31, 2024). Research-use biofluids and tissues represented ~49% and ~39% of revenue in 2024 and 2023, respectively, while one customer accounted for ~29% of 2024 revenue. The company disclosed a $1.0 million loan with an 18% note, capital raises including ~$1.49 million net ATM proceeds and a ~$5.0 million offering, capitalized software and sequenced-data intangible assets, an accumulated deficit, and material litigation and contract disputes (including a platform service disruption from January 25 to February 12, 2025). Nasdaq notified the company on June 4, 2025 of noncompliance with minimum stockholders’ equity and the company has submitted a compliance plan.
iSpecimen Inc. furnished an update on its strategic initiative to integrate digital assets into its business model. The company is pursuing plans to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem. Since outlining this approach in August 2025, iSpecimen reports that several cryptocurrency-related companies have approached it with opportunities involving tokenized real-world assets and highly ranked cryptocurrencies. In parallel, the company continues meetings focused on developing the Solana-based treasury program. The update was provided via a press release, which is furnished for informational purposes and not deemed filed for liability purposes.
iSpecimen, Inc. (ISPC) operates a bioprocurement marketplace matching researchers with human specimens and associated data. The company reported concentrated, transactional revenue with research-use specimens (biofluids, tissues, cells) representing a substantial portion of sales and one customer accounting for ~29% of 2024 revenue. As of December 31, 2024 the company had $1.88 million cash and an accumulated deficit of ~$71.9 million. In 2024 the company raised capital through a $1.0 million short-term loan (18% interest), an ATM program that generated gross proceeds of ~$1.49 million (net ~$1.24 million), and an October 31, 2024 offering that produced gross proceeds of ~$4.998 million (net ~$4.632 million). The company completed a 1-for-20 reverse stock split in September 2024 and regained Nasdaq bid-price compliance. Material operational issues included a third-party platform disruption in January–February 2025 that temporarily shut the marketplace; related disputes and settlement activity are ongoing. The filing discloses significant customer concentration, nonrecurring transactional revenue, ongoing litigation and sales tax exposures, and efforts to reduce costs and capital needs.
iSpecimen Inc. reported that it has successfully completed Milestone 1 of its digital transformation program powered by Salestack Solutions. This first milestone covers installing the new Salestack platform and putting modern technology infrastructure in place.
With this foundation built, the company plans to move to Milestone 2, which will focus on integrating all parts of the business with the Salestack platform to improve operational efficiency, customer engagement, and data management across the organization.
iSpecimen Inc. (ISPC) filed an S-1 describing a marketplace that matches researchers with human biospecimens and related data. The company operates a technology-enabled bioprocurement marketplace that ingests and harmonizes supplier data, supports workflow and compliance, and sells a range of specimen products including remnant and research-use biofluids, tissues, and hematopoietic stem and immune cells.
Key facts disclosed include a 1-for-20 reverse stock split effective September 13, 2024; a $1.0 million short-term loan at 18% interest closed September 25, 2024; research-use specimens represented approximately 49% of revenue in 2024 (39% in 2023); one customer represented ~29% of revenue in 2024; the company reported an accumulated deficit and limited cash balances and has used debt and equity raises (including an ATM and a registered offering) to fund operations. The filing discloses litigation and a third-party platform outage in early 2025 that disrupted the marketplace and related settlement activity.